In this interview from AAO 2018, Dr. Gail Schwartz describes 2 new glaucoma medications on the market: latanoprostene bunod (Vyzulta) and netarsudil (Rhopressa).

In this lecture from Glaucoma Subspecialty Day 2017, Dr. Janey Wiggs describes new advances in gene therapy for glaucoma.

Drs. Joel Schuman and Fabio Lavinsky discuss novel IOP-lowering agents, which include Rho-associated protein kinase (ROCK) inhibitors (netarsudil), nitric oxide–donating prostaglandin analogs (latanoprostene bunod), and adenosine receptor agonists.

Using a search of trials listed on clinicaltrials.gov, Dr. Gary Novack describes the status of new glaucoma drugs that are in phase 1, 2, or 3 trials. His search uncovered 2 drugs: latanoprostene bunod 0.024%, a prostaglandin-releasing nitric oxide, and netarsudil 0.02%, a Rho-kinase inhibitor with norepinephrine reuptake inhibition.

In this presentation, Dr. Janet Searle discusses devices that are being developed to reduce medication dosing frequency for patients with glaucoma, including the bimatoprost Helios ring, the topical ophthalmic drug delivery device (TODDD), drug-eluting contact lenses, and the Bionode combined contact lens, gold trace, and eyeglass device.

This lecture from AGS 2018 a panel discusses how best to handle an 82-year-old patient with glaucoma in the right eye worse than the left, the right eye has been on max drops, no glaucoma surgery, but clear progression, the pressures have been 11-13, and the left eye has been stable.

In this interview from Glaucoma 360, Dr. Jamie Brandt, MD, discuss developments in glaucoma drug delivery, including how sustained delivery implants and home monitoring could revolutionize the management of glaucoma.

In this interview from AAO 2017, Dr. Peter Netland discusses management strategies for uveitic glaucoma in adults, including surgical, laser and medical therapies.

Weekly case challenge